Overview of Semaglutide
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that was first approved for the treatment of type 2 diabetes in 2017. It helps lower blood sugar levels by stimulating the release of insulin when blood sugar is high. Semaglutide also slows digestion and decreases appetite, which can lead to weight loss. This makes it useful not only for diabetes but also for chronic weight management.
Initially marketed under the brand name Ozempic, semaglutide was approved for chronic weight management in 2021 under the name Wegovy. Both formulations contain the same active ingredient.
Semaglutide is given as a once-weekly subcutaneous injection, meaning it's injected into the fatty tissue under the skin.